

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



東北虎藥業股份有限公司
NORTHEAST TIGER PHARMACEUTICAL CO., LTD*
(A joint stock limited company incorporated in the People's Republic of China)
(Stock Code: 08197)

CHANGE OF PRINCIPAL PLACE OF BUSINESS IN HONG KONG

The board of directors (the “Board”) of Northeast Tiger Pharmaceutical Co., Ltd (the “Company”) announces that the principal place of business of the Company in Hong Kong will be changed to Suite 2002, 20/F., Haleson Building, 1 Jubilee Street, Central, Hong Kong with effect from 20 September 2016.

By Order of the Board
東北虎藥業股份有限公司
Northeast Tiger Pharmaceutical Co., Ltd.*
Chairman
Wang Shaoyan

Jilin, the PRC, 19 September 2016

As at the date of this announcement, the Company’s executive directors are Wang Shaoyan, Cui Bingyan and Qin Haibo; the Company’s non-executive directors are Guo Aiqun and Cao Yang and the Company’s independent non-executive directors are Zhao Zhen Xing, Chen Youfang and Hui Lai Yam.

This announcement, for which the directors of the Company collectively and individually accept full responsibility, includes particulars given in compliance with the GEM Listing Rules for the purpose of giving information with regard to the Company. The directors of the Company, having made all reasonable enquiries, confirm that to the best of their knowledge and belief the information contained in this announcement is accurate and complete in all material respects and not misleading or deceptive, and there are no other matters the omission of which would make any statement herein or this announcement misleading.

** for identification purposes only*